Backed by decades of continuous innovation informed by patient feedback, LifeVest continues to set the standard in the WCD market. LifeVest delivers highly effective, safe therapy for patients at risk ...

CHELMSFORD, Mass.--(BUSINESS WIRE)--The ZOLL LifeVest ® team is “going red” for Heart Month in February 2026 in support of the American Heart Association and their Go Red for Women ® initiative to ...

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the LifeVest® wearable cardioverter defibrillator ...